Takeda Pharmaceuticals U.S.A. Inc. and several other generic drug makers face a new antitrust suit from wholesalers alleging that they conspired to restrict generic competition for the gout medication Colcrys.
Takeda maintained monopoly power in the market for its top-selling Colcrys and engaged in illegal settlement and license agreements to impair generic competition, according to a complaint filed Monday in US District Court for the Eastern District of Pennsylvania.
The plaintiffs, which include drug wholesaler Valley Wholesale Drug Co. LLC and North Carolina Mutual Wholesale Drug Co., alleged they paid inflated prices for Colcrys as a result of the agreements. ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.